'pemetrexed' can also refer to...



pemetrexed n.

Pemetrexed and malignant pleural mesothelioma

Clinical studies of pemetrexed and gemcitabine combinations

Has Pemetrexed revived the Doctrine of Equivalence?

Pemetrexed: A multitargeted antifolate agent with promising activity in solid tumors

Dose escalation study of carboplatin–pemetrexed followed by maintenance pemetrexed for elderly patients with advanced nonsquamous nonsmall-cell lung cancer

First-line icotinib versus cisplatine/pemetrexed plus pemetrexed maintenance therapy in lung adenocarcinoma patients with EGFR mutation (CONVINCE)

Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers

Phase II study of pemetrexed in breast cancer patients pretreated with anthracyclines

Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM)

Gemcitabine and pemetrexed combination: the key role of the sequence of drugs administration

437PActivity of S-1 for non-small cell lung cancer pretreated with pemetrexed

Successful Treatment of Gastric Adenocarcinoma in a Meckel's Diverticulum with Pemetrexed Plus Carboplatin

An eQTL-based method identifies CTTN and ZMAT3 as pemetrexed susceptibility markers

Upfront association of carboplatin plus pemetrexed in patients with brain metastases of lung adenocarcinoma

1627TiPONCOS-102 and pemetrexed/cisplatin in patients with unresectable malignant pleural mesothelioma

Pemetrexed plus carboplatin versus pemetrexed in pretreated patients with advanced non-squamous non-small-cell lung cancer: treating the right patients based on individualized treatment effect prediction


More Like This

Show all results sharing this subject:

  • Clinical Pharmacology and Therapeutics


Show Summary Details

Quick Reference

A chemotherapeutic drug (a folate antimetabolite) used to treat pleural mesothelioma and non-small-cell lung cancer. TN Alimta.

Subjects: Clinical Pharmacology and Therapeutics.

Reference entries

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.